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Although two-dose mRNA vaccination provides excellent protection against 
SARS-CoV-2, there is little information about vaccine efficacy against variants of 
concern (VOC) in individuals above eighty years of age1. Here we analysed immune 
responses following vaccination with the BNT162b2 mRNA vaccine2 in elderly 
participants and younger healthcare workers. Serum neutralization and levels of 
binding IgG or IgA after the first vaccine dose were lower in older individuals, with a 
marked drop in participants over eighty years old. Sera from participants above eighty 
showed lower neutralization potency against the B.1.1.7 (Alpha), B.1.351 (Beta) and P.1. 
(Gamma) VOC than against the wild-type virus and were more likely to lack any 
neutralization against VOC following the first dose. However, following the second 
dose, neutralization against VOC was detectable regardless of age. The frequency of 
SARS-CoV-2 spike-specific memory B cells was higher in elderly responders (whose 
serum showed neutralization activity) than in non-responders after the first dose. 
Elderly participants showed a clear reduction in somatic hypermutation of 
class-switched cells. The production of interferon-γ and interleukin-2 by SARS-CoV-2 
spike-specific T cells was lower in older participants, and both cytokines were 
secreted primarily by CD4 T cells. We conclude that the elderly are a high-risk 
population and that specific measures to boost vaccine responses in this population 
are warranted, particularly where variants of concern are circulating.
Vaccines designed to elicit protective immune responses remain 
the key hope for containing the COVID-19 pandemic caused by 
SARS-CoV-2. In particular, mRNA vaccines have shown excellent 
efficacy when administered as two doses separated by a three- or 
four-week gap2,3. There is increasing evidence that neutralizing 
responses are a correlate of protection4–6. Few trial data on neutral-
izing responses or vaccine efficacy in individuals above the age of 
80 are available1. This is even more pertinent for settings in which 
a dosing interval of 12–16 weeks or more has been implemented to 
maximize the administration of first doses7. In addition, the emer-
gence of new variants with increased transmissibility8 and reduced 
sensitivity to vaccine-elicited antibodies9, and for which vaccines 
are less able to prevent infection10, has raised fears for vulnerable 




We studied 140 participants who had received at least one vaccination 
(median age 72 years (interquartile range (IQR) 44–83), 51% female; 
Extended Data Fig. 1). We first validated the use of a pseudotyped virus 
(PV) system to investigate neutralization, by comparing geometric mean 
titres (GMTs) between PVs expressing the Wuhan-1 D614G spike (referred 
to here as wild-type) and a B.1 lineage live virus isolate, using sera isolated 
from thirteen individuals after two vaccine doses (Extended Data Fig. 2). 
We observed a high correlation between the two approaches, consistent 
with other findings11, and proceeded with the PV system.
We explored the association between age and ability to neutralize 
virus by plotting the proportion of individuals whose sera produced 
detectable virus neutralization after the first dose at a given age. This 
analysis showed a nonlinear relationship with a marked drop around 
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the age of 80 years (Fig. 1a). Given this nonlinear change in a correlate of 
protection, we performed selected subsequent analyses with age both 
as a continuous variable and as a categorical variable. When individuals 
aged 80 years or more were tested between 3 and 12 weeks after their 
first dose, around half showed no evidence of neutralization (Extended 
Data Fig. 2). Geometric mean neutralization titre (GMT) was lower in 
participants aged 80 years or more than in younger individuals (48.2 
(95% confidence interval (CI) 34.6–67.1) versus 104.1 (95% CI 69.7–155.2), 
P = 0.004; Extended Data Table 1, Fig. 1b). GMT showed evidence of an 
inverse association with age (Extended Data Fig. 2). The GMT following 
the second dose was significantly higher in individuals for whom there 
had been a 12-week interval between doses compared with a 3-week 
interval between doses (Extended Data Fig. 2). A clinically accredited 
assay for N antibodies9 showed evidence that five individuals in each 
group had previously been infected with SARS-CoV-2 (Extended Data 
Table 1), and we adjusted for this in multivariable analyses (Extended 
Data Tables 2, 3). Neutralizing titres for sera from vaccinated individuals 
were higher after the second dose than after the first dose, regardless of 
age (Fig. 1b). In participants who had suboptimal or no neutralization 
after dose 1, and who subsequently received the second dose within the 
study period (Fig. 1c), all but two elderly participants responded with 
an increase in neutralization activity (Extended Data Table 1, Fig. 1b).
Given our observation that participants aged 80 years or more had 
lower neutralization responses following the first dose than younger 
individuals, we hypothesized that this could lead to sub-protective 
neutralizing responses against the B.1.1.7, B.1.351 and P.1 VOCs, which 
were first identified in the UK, South Africa and Brazil, respectively 
(Extended Data Fig. 2). We therefore examined serum neutralization 
by age group against PVs bearing the wild-type spike protein or spike 
proteins from the three VOCs (Fig. 1d, e). There was a clear reduction 
in neutralizing titres against VOCs (Fig. 1d), and titres were lower 
for individuals over 80 years old than for younger individuals. The 
proportions of individuals with detectable neutralization showed 
a similar pattern (Fig. 1e, Extended Data Tables 2, 3). Following the 
second dose, although there were differences in GMT for the VOCs 
between the age groups (Fig. 1f), nearly all participants across age 
groups had detectable neutralization responses across the VOCs 
tested (Fig. 1g).
B cell responses to mRNA vaccination
We measured binding antibody responses to the full-length wild-type 
(Wuhan-1) spike protein9. Levels of IgG and all IgG subclasses against 
spike protein increased between vaccine doses (Fig. 2a), and were similar 
after the second dose to those observed following natural infection. Like 
the neutralization titres, levels of IgG against spike declined with age 
(Fig. 2b, Extended Data Fig. 3). IgG and its subclasses correlated with 
serum neutralization (Fig. 2c, Extended Data Fig. 3). The concentrations of 
total and subclass anti-spike IgGs were significantly lower in participants 
aged 80 or older than in the younger group (Fig. 2d). IgA responses also 
increased between the two doses and correlated with neutralization 
after dose 1 (Extended Data Fig. 3). In addition, phenotyping of periph-
eral blood mononuclear cells (PBMCs) by flow cytometry showed that 



















































































































































































































































































































































































































Fig. 1 | SARS-CoV-2 neutralization by 
sera from BNT162b2 vaccinated 
individuals. a, Proportion of individuals 
with detectable serum neutralization of 
PV after the first dose of Pfizer BNT162b2 
vaccine by age. Cut-off for serum 
neutralization is an inhibitory dilution at 
which 50% inhibition of infection is 
achieved (ID50) of 20. Shading, 95% CI.  
b, Serum neutralization of PV after dose 1 
(blue) and dose 2 (red) by age group  
(<80 years (n = 79), ≥ 80 years (n = 59)).  
c, Neutralization curves for serum from 
two individuals (ID 4 and ID 8) with lower 
responses after the first dose (blue) and 
increased neutralization activity after the 
second dose (red) of BNT162b2 against 
pseudovirus expressing wild-type spike 
protein (D614G). Data shown as 
mean ± s.e.m. of technical replicates.  
d, f, Neutralization of SARS-CoV-2 VOCs  
by sera after dose 1 (d) and dose 2 (f) of 
BNT162b2. d, WT, n = 138; B.1.1.7, n = 135; 
B.1.351, n = 82; P.1, n = 82. f, WT, n = 64; 
B.1.1.7, n = 53; B.1.351, n = 32; P.1, n = 32. 
Data shown as GMT ± s.d. e, g, The 
proportion of participant vaccine sera 
with neutralization activity against 
wild-type and mutant spike proteins after 
dose 1 (e) and dose 2 (g) (ID50 > 1 in 20 
dilution of sera). GMT ± s.d. are 
representative of two independent 
experiments each with two technical 
repeats. Mann–Whitney test was used for 
unpaired comparisons and Wilcoxon 
matched-pairs signed rank test for paired 
comparisons. *P < 0.05, **P < 0.01, 
****P < 0.0001; NS, not significant. HS, 
human AB serum control.
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proportion of spike-specific IgG+IgM−CD19+ memory B cells (Fig. 3e). Nota-
bly, the proportion of these cells did not differentiate neutralizers from 
non-neutralizers in the under-80 group (Fig. 3e, Extended Data Fig. 4).
We performed B cell repertoire sequencing on bulk PBMCs to assess 
isotype and variable gene usage, somatic hypermutation and diversity 
of the repertoire between the two age groups and in relation to neutrali-
zation. There were no differences in isotype proportions between the 
two age groups (Extended Data Fig. 5), or by neutralization (Fig. 3a). 
We found an increase in usage of the immunoglobulin heavy variable 
4 (IGHV4) family in the older age group, with an increased propor-
tion of IGHV4.34, IGHV4.39, IGHV4.59 and IGHV4.61, whereas in the 
younger age group there was an increase in usage of the IGHV1 family, 
with increases in IGHV1.18 and IGHV1.69D (Fig. 3b). We did not find any 
significant differences in V gene usage associated with neutralization 
(Extended Data Fig. 5).
Differences in somatic hypermutation could affect neutralization 
through antibody affinity maturation. We found that participants 
aged 80 years or more had a lower level of somatic hypermutation in 
class-switched B cell receptors (BCRs) than the younger group, and that 
the difference was driven by the IgA1/2 isotype (Fig. 3c). We also did 
not find any relationship between measures of diversity and neutrali-
zation potency or age group (Fig. 3d, Extended Data Fig. 5). We next 
examined the B cell repertoire for public clones known to be associ-
ated with SARS-CoV-2 neutralization. We explored the convergence 
between BCR clones in our study and the CoV-AbDab database12 and 
found that participants under 80 years of age had a higher frequency 
of convergent clones, in keeping with increased neutralization, when 
compared with the older group (Fig. 3e).
T cell responses to mRNA vaccination
Although it is increasingly recognized that neutralizing antibodies 
dominate protection against initial infection4,13, T cells might limit 
disease progression5 when neutralizing antibody titres are low14. We 
therefore determined the T cell response to SARS-CoV-2 spike protein in 
vaccinated individuals by stimulating PBMCs with overlapping peptide 
pools to the wild-type SARS-CoV-2 spike, using an interferon-γ (IFNγ) 
and interleukin-2 (IL-2) FluoroSpot assay to count spike-specific T cells. 
When we plotted IFNγ-spike specific T cell responses against age as a 
continuous variable, there was a negative correlation with a drop-off at 
around 80 years (Fig. 4a). A similar effect, albeit less pronounced, was 
seen for IL-2 (Fig. 4b). However, there did not appear to be a relationship 
between cytokine production by PBMCs and neutralization titre after 
the first dose (Extended Data Fig. 6).
Following the first dose of vaccine, the frequency of IFNγ-secreting 
T cells against a CEF+ peptide pool that included cytomegalovirus 
(CMV)-, Epstein-Barr virus (EBV)- and influenza-specific peptides did 
not differ by age category and was similar to healthy SARS-CoV-2 unex-
posed controls (Extended Data Fig. 6). This indicates that differences 
in observed responses were likely to be vaccine-specific rather than 
resulting from generalized suboptimal T cell responses or immune 
paresis. However, IFNγ spike-specific T cell responses were signifi-
cantly larger in immunized individuals below 80 years of age than in 
an unexposed population of the same age (Fig. 4c). However, in par-
ticipants aged 80 years or more, the IFNγ spike-specific T cell response 
following the first dose did not differ from that of unexposed con-
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Fig. 2 | SARS-CoV-2 spike-binding antibody responses and SARS-CoV-2 
spike-specific memory B cells in blood following vaccination with 
BNT162b2. a, Total anti-spike IgG and subclasses after first and second doses 
of vaccine and in individuals with prior COVID-19. MFI, mean fluorescence 
intensity. b, Pearson’s correlation (r) between anti-spike IgG binding antibody 
responses after first dose and age (n = 134). c, Pearson’s correlation between 
anti-spike IgG (n = 134) binding antibody responses and neutralization by sera 
against SARS-CoV-2 in a spike lentiviral pseudotyping assay expressing 
wild-type spike (D614G). d, Anti-spike IgG subclass responses to first dose 
vaccine stratified by age (<80 and ≥80 years). e, CD19+ memory B cells (left, as 
percentage of PBMCs) and SARS-CoV-2 spike-specific CD19+IgG+IgM− memory 
B cells (right, as percentage of all memory B cells) from FACS-sorted PBMCs. 
n = 16 for ≥80 years, n = 16 for <80 years; stratified by neutralizing response 
after first dose, n = 8 in each category. MFI – mean fluorescence intensity. 
Mann–Whitney test was used for unpaired comparisons. *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001; NS, not significant. Scatter plots show linear 
correlation line bounded by 95% CI; β, slope/regression coefficient.  
Error bars, s.d.
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significantly higher in both vaccinated groups than in unexposed con-
trols (Fig. 4d). Notably, although spike-specific IFNγ and IL-2 responses 
in PBMCs after the first dose of vaccine were similar to those found 
after natural infection (Extended Data Fig. 6), the second dose did 
not appear to increase these responses, either overall (Extended Data 
Fig. 6) or within age categories (Fig. 4e, f). Following depletion of CD4 
or CD8 T cells, the majority of IFNγ and IL-2 production was from CD4+ 
T cells in vaccinated individuals (Fig. 4g, h). Those aged 80 or more 
had markedly lower spike-specific IL-2 CD4+ T cell responses than their 
younger counterparts (Fig. 4g).
CMV serostatus has been associated with poorer responses to vac-
cination and infections15,16. The rate of CMV IgG positivity was higher 
in the older age group (Extended Data Fig. 6); unexpectedly, though, 
CMV-positive individuals in this group had significantly higher IFNγ, 
but not IL-2, responses to SARS-CoV-2 spike peptides than CMV-negative 
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Fig. 3 | B cell repertoire following vaccination with first dose of BNT162b2. 
a, Isotype usage according to unique VDJ sequence in participants <80 (n = 22) 
or ≥80 years old (n = 28) and association with neutralization of spike 
pseudotyped virus. Neutralization cut-off for 50% neutralization was set at 20. 
Mann–Whitney U-test. b, Heat map showing differences in V gene usage 
between the <80 and ≥80 groups. Mann–Whitney U-test with Benjamini–
Hochberg false discovery rate (FDR) correction; *P < 0.1. c, Mean somatic 
hypermutation for participants <80 or ≥80 years old, grouped according to 
isotype class. Mann–Whitney U-test. d, Diversity indices for neutralizing and 
non-neutralizing groups. The inverse is depicted for Simpson’s index. t-test.  
e, BCR comparison of patients in the two age groups for the first 50 days after 
vaccination (<80, n = 27; ≥80, n = 5) with public clones known to be associated 
with SARS-CoV-2 using the CoV-AbDab database12. Clones from participants 
and the database were co-clustered based on matching IGHV and IGHJ 
segments, matching CDR-H3 region length and 85% CDR-H3 sequence amino 
acid homology. One-sided t-test. For boxplots: centre line, median; box,  
25th–75th percentile; whiskers, 1.5× IQR.
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Autoantibodies and inflammatory molecules
Finally, we investigated the possibility of interactions between senes-
cence and mRNA vaccine responses. Autoantibodies and inflammatory 
cytokines or chemokines are associated with immune senescence17. We 
first measured a panel of autoantibodies in the sera of 101 participants 
following the first dose of the BNT162b2 vaccine. Eight participants had 
autoantibodies against myeloperoxidase (anti-MPO), two against fibril-
larin and one against cardiolipin (Extended Data Fig. 7). As expected, all 
but one of the participants with anti-MPO autoantibodies were over the 
age of 80 years (Extended Data Fig. 7). There was a trend towards reduced 
anti-spike IgG levels and serum neutralization against the wild-type and 
B.1.17 spike proteins in participants with autoantibodies, although this 
did not reach statistical significance (probably owing to the small sample 
size; Extended Data Fig. 7). Next, we explored the association between 
serum cytokines or chemokines and neutralization of SARS-CoV-2 PV, as 
well as their association with age. PIDF, a known senescence-associated 
secretory phenotype (SASP) molecule, was the only molecule that was 
enriched in sera from participants aged over 80 years, and there was no 
association between any of these molecules and the ability of sera to 
neutralize SARS-CoV-2 PVs (Extended Data Fig. 7).
Discussion
Neutralizing antibodies are a likely correlate of protection against 
SARS-CoV-2 infection, as suggested by vaccine efficacy studies, pre-
clinical studies in mice and non-human primates, and data from the 
early use of convalescent plasma in elderly patients4,5,10,13,14,18,23. There 
is a lack of data on neutralizing antibody immune responses following 
mRNA vaccination in the elderly, and no data, to our knowledge, on 
variants of concern in this group. In a clinical study that specifically 
looked at older adults vaccinated with BNT162b2, the GMT after the 
first dose was 12 in a set of 12 subjects between ages of 65 and 85 years, 
rising to 149 seven days after the second dose1. Furthermore, in a study 
of the Moderna 1273 mRNA vaccine in individuals above 55 years of 
age, neutralization was detectable only after the second dose, whereas 
binding antibodies were detectable after both doses19. In a randomized 
phase I study on BNT162b1 in younger (18–55 years) and older adults 
(65–85 years), virus neutralization was lower in the older age group 22 
days after the first dose20. These data reflect the finding that responses 
to the ChAdOx1 nCov-19 (AZD-1222) vaccine were lower in older than in 
younger mice, and the difference was overcome by booster dosing21.
Here, in a cohort of 140 individuals, we have shown not only an inverse 
relationship between age and neutralizing responses following the first 
dose of BNT162b2, but also a more precipitous decline around the age of 
80 years. Individuals aged 80 or more were prioritized for vaccination in 
the UK and elsewhere, as they represented the group at greatest risk of 
severe COVID-1922. We found that around half of those above the age of 80 
have a suboptimal neutralizing antibody response after the first dose of 
BNT162b2, accompanied by lower T cell responses compared to younger 
individuals. Individuals over 80 years of age differed from the younger 
group in four main respects that could explain poorer neutralization of 
SARS-CoV-2. First, serum IgG levels were lower, accompanied by a lower 
proportion of peripheral spike-specific IgG+IgM−CD19+ memory B cells. 
Second, the elderly displayed lower somatic hypermutation in the BCR 
gene. Third, the elderly had lower enrichment for public BCR clonotypes 
that are associated with neutralization. And fourth, the older group dis-
played a marked reduction in IL-2-producing spike-reactive CD4+ T cells. 
Therefore, possible explanations for their poorer neutralizing responses 
include lower concentrations of antibodies (quantity) and/or lower-affinity 
antibodies (quality) resulting from B cell selection, reduced CD4+ T cell 
help, or a combination of both. These data parallel those in aged mice, 
where ChAdOx1 nCov-19 (AZD-1222) vaccine responses were reported to 
be lower than in younger mice, and this was overcome by booster dosing21.
Critically, we show that elderly individuals are likely to be at greater 
risk from VOCs, as a greater proportion of individuals in the over-80 age 
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Fig. 4 | T cell responses to BNT162b2 vaccine after the first and second 
doses. a, b, FluoroSpot analysis by age for IFNγ (a) and IL-2 (b) T cell responses 
specific to SARS-CoV-2 spike protein peptide pool following PBMC stimulation. 
SFU, spot-forming units. Scatter plots show linear correlation line bounded by 
95% CI; β, slope/regression coefficient. c, d, FluoroSpot analysis for IFNγ (c) and 
IL-2 (d) T cell responses specific to SARS-CoV-2 spike protein peptide pool 
following stimulation of unexposed PBMCs (stored PBMCs from 2014–2016, 
n = 20) and PBMCs from vaccinated individuals (<80 IFNγ, n = 46; <80 IL-2, 
n = 44; ≥80 IFNγ, n = 35; ≥80 IL-2, n = 27) three weeks or more after the first dose 
of BNT162b2. e, f, FluoroSpot analysis for IFNγ (e) and IL-2 (f) T cell responses 
specific to SARS-CoV-2 spike protein peptide pool following stimulation of 
unexposed PBMCs (n = 20) and PBMCs from vaccinated individuals three weeks 
after the first or second dose (first dose: <80 IFNγ, n = 46; <80 IL-2, n = 45; ≥80 
IFNγ, n = 31; ≥80 IL-2, n = 19; second dose: <80 IFNγ, n = 15; <80 IL-2, n = 15; ≥80 
IFNγ, n = 24; ≥80 IL-2, n = 24). g, h, FluoroSpot analysis for IL-2 (g) and IFNγ (h) 
CD4 and CD8 T cell responses specific to SARS-CoV-2 spike protein peptide 
pool following stimulation after column-based PBMC separation. Mann–
Whitney test was used for unpaired comparisons and Wilcoxon matched-pairs 
signed rank test for paired comparisons. *P < 0.05, ***P < 0.001, ****P < 0.0001; 
NS, not significant. Error bars, s.d.
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group showed no neutralizing activity to P.1 and B.1.1.7 after the first dose. 
Reassuringly, we observed neutralizing responses across all age groups 
after the second dose, although further work is needed to understand the 
effect of age on the durability of immune responses following vaccination.
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Methods
Study design
Community participants or healthcare workers who received their 
first dose of the BNT162b2 vaccine between 14 December 2020 and 
10 February 2021 were consecutively recruited at Addenbrooke’s 
Hospital into the COVID-19 cohort of the NIHR Bioresource. Partici-
pants were followed up for up to 3 weeks after receiving their second 
dose of the BNT162b2 vaccine. They provided blood samples 3 to 12 
weeks after their first dose and again 3 weeks after the second dose 
of the vaccine. Consecutive participants were eligible without exclu-
sion. The exposure of interest was age, categorized into two exposure 
levels (<80 and ≥80 years). The outcome of interest was inadequate 
vaccine-elicited serum antibody neutralization activity at least 3 weeks 
after the first dose. This was measured as the dilution of serum required 
to inhibit infection by 50% (ID50) in an in vitro neutralization assay. 
An ID50 of 20 or below was deemed inadequate neutralization. Bind-
ing antibody responses to the spike, receptor-binding domain (RBD) 
and nucleocapsid were measured by multiplex particle-based flow 
cytometry and spike-specific T cell responses were measured by IFNγ 
and IL-2 FluoroSpot assays. Measurement of serum autoantibodies and 
characterization of the B cell receptor (BCR) repertoire following the 
first vaccine dose were exploratory outcomes.
We assumed a risk ratio of non-neutralization in the ≥80 years group 
compared with the <80 years group of 5. Using an alpha of 0.05 and 
power of 90% required a sample size of 50 with a 1:1 ratio in each group.
Ethical approval
The study was approved by the East of England – Cambridge Central 
Research Ethics Committee (17/EE/0025). PBMCs from unexposed 
volunteers previously recruited by the NIHR BioResource Centre Cam-
bridge through the ARIA study (2014–2016) were used with ethical 
approval from the Cambridge Human Biology Research Ethics Com-
mittee (HBREC.2014.07) and currently North of Scotland Research 
Ethics Committee 1 (NS/17/0110).
Statistical analyses
Descriptive analyses of demographic and clinical data are presented 
as median and IQR when continuous and as frequency and proportion 
(%) when categorical. Differences between continuous and categori-
cal data were tested using Wilcoxon rank sum and Chi-square tests, 
respectively. Logistic regression was used to model the association 
between age group and neutralization by vaccine-elicited antibodies 
after the first dose of the BNT162b2 vaccine. The effects of sex and time 
interval from vaccination to sampling as confounders were adjusted 
for. Linear regression was also used to explore the association between 
age as a continuous variable and log-transformed ID50, binding anti-
body levels, antibody subclass levels and T cell response after dose 1 
and dose 2 of the BNT162b2 vaccine. Bonferroni adjustment was made 
for multiple comparisons in the linear correlation analyses between 
binding antibody levels, ID50, age and T cell responses. The Pearson’s 
normally distributed correlation coefficient for linear data and Spear-
man’s non-normally distributed correlation for nonlinear data were 
reported. Statistical analyses were done using Stata v13, Prism v9 and 
R (version 3.5.1).
Generation of mutants and pseudotyped viruses
Wild-type pseudotyped virus (bearing mutation D614G), B.1.1.7 pseu-
dotyped viruses (bearing mutations Δ69/70, Δ144, N501Y, A570D, 
D614G, P681H, T716I and S982A and D1118H), B.1.351 pseudotyped virus 
(bearing mutations L18F, D80A, D215G, Δ242-4, R246I, K417N, E484K, 
N501Y, D614G, A701V) and P.1 pseudotyped virus (bearing mutations 
L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, 
T1027I and V1176F) were generated. In brief, amino acid substitutions 
were introduced into the D614G pCDNA_SARS-CoV-2_S plasmid as 
previously described23 using the QuikChange Lightening Site-Directed 
Mutagenesis kit, according to the manufacturer’s instructions (Agilent 
Technologies). Sequences were verified by Sanger sequencing. The 
pseudoviruses were generated in a triple plasmid transfection system 
whereby the spike-expressing plasmid along with a lentviral packaging 
vector (p8.9) and luciferase expression vector (psCSFLW) were trans-
fected into 293T cells (a gift from Greg Towers; tested for mycoplasma) 
with Fugene HD transfection reagent (Promega). The viruses were 
harvested after 48 h and stored at −80 °C. TCID50 was determined by 
titration of the viruses on 293T cells expressing ACE-2 and TMPRSS224.
Pseudotyped virus neutralization assays
Spike pseudotype assays have been shown to have similar charac-
teristics as neutralization testing using fully infectious wild-type 
SARS-CoV-211. Virus neutralization assays were performed on 293T cells 
transiently transfected with ACE2 and TMPRSS2 using SARS-CoV-2 spike 
pseudotyped virus expressing luciferase24. Pseudotyped virus was incu-
bated with serial dilutions of heat-inactivated human serum samples or 
sera from vaccinated individuals in duplicate for 1 h at 37 °C. Virus and 
cell-only controls were also included. Then, freshly trypsinized 293T 
ACE2/TMPRSS2-expressing cells were added to each well. Following 48 
h incubation with 5% CO2 at 37 °C, luminescence was measured using 
the Steady-Glo Luciferase assay system (Promega). Neutralization 
was calculated relative to virus-only controls. Dilution curves were 
presented as a mean neutralization with s.e.m. ID50 values were calcu-
lated in GraphPad Prism. The limit of detection for 50% neutralization 
was set at an ID50 of 20. The ID50 within groups were summarized as 
a geometric mean titre (GMT) and statistical comparison between 
groups were made with Mann–Whitney or Wilxocon ranked sign tests.
Live virus serum neutralization assays
A549-ACE2-TMPRSS2 cells were seeded at a cell density of 2.4 × 104 per 
well in a 96-well plate 24 h before inoculation. Serum was titrated start-
ing at a final dilution of 1:50 with live B.1 virus PHE2 (EPI_ISL_407073) 
isolate being added at a multiplicity of infection (MOI) of 0.01. The 
mixture was then incubated for 1 h before being added to the cells. 
Seventy-two hours after infection, the plates were fixed with 8% for-
maldehyde and then stained with Coomassie blue for 30 min. The 
plates were washed and dried overnight before using a Celigo Imaging 
Cytometer (Nexcelom) to measure the staining intensity. Percentage 
cell survival was determined by comparing the intensity of the stain-
ing to an uninfected well. A nonlinear sigmoidal 4PL model (Graphpad 
Prism 9) was used to determine the IC50 for each serum. The correlation 
between log-transformed ID50 obtained from the pseudotyped virus 
and live virus systems were explored using linear regression. Pearson’s 
correlation coefficient was determined.
SARS-CoV-2 serology by multiplex particle-based flow 
cytometry (Luminex)
Recombinant SARS-CoV-2 nucleocapsid, spike and RBD were covalently 
coupled to distinct carboxylated bead sets (Luminex) to form a 3-plex 
and analysed as previously described25. Specific binding was reported 
as mean fluorescence intensities (MFI).
CMV serology
HCMV IgG levels were determined using an IgG enzyme-linked immu-
nosorbent assay (ELISA), HCMV Captia (Trinity Biotech) according 
to the manufacturer’s instructions, on plasma derived from clotted 
blood samples.
Serum autoantibodies
Serum was screened for the presence of autoantibodies using the Proto-
Plex autoimmune panel (Life Technologies) according to the manufac-
turer’s instructions. In brief, 2.5 μl serum was incubated with Luminex 
MagPlex magnetic microspheres in a multiplex format conjugated to 
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19 full-length human autoantigens (cardiolipin, CENP B, H2a(F2A2) 
and H4 (F2A1), Jo-1, La/SS-B, Mi-2b, myeloperoxidase, proteinase-3, 
pyruvate dehydrogenase, RNP complex, Ro52/SS-A, Scl-34, Scl-70, 
Smith antigen, thyroglobulin, thyroid peroxidase, transglutaminase, 
U1-snRNP 68, and whole histone) along with bovine serum albumin 
(BSA). Detection was undertaken using goat-anti-human IgG-RPE in a 
96-well flat-bottomed plate and the plate was read in a Luminex xMAP 
200 system. Raw fluorescence intensities (FI) were further processed 
in R (version 3.5.1) Non-specific BSA-bound FI was subtracted from 
background-corrected total FI for each antigen before log2 transforma-
tion and thresholding. Outlier values (Q3 + 1.5 × IQR) in each distribution 
were defined as positive.
Serum chemokine and cytokine analysis
Serum proteins were quantified using a validated electrochemilumi-
nescent sandwich assay quantification kit (Mesoscale Discovery VPlex) 
according to the manufacturer’s instructions. In brief, both sera and 
standard calibration controls were incubated with SULFO-tagged anti-
bodies targeting IFNγ, IL-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, 
TNFα, GC-CSF, IL-1α, IL-12, IL-15, IL-16, IL-17A, IL-5, IL-7, TNFβ, VEGF, MCP1, 
MCP4, eotaxin, eotaxin3, IP10, MDC, MIP1α, MIP1β, TARC, IL-17B, IL-17C, 
IL-17D, IL-1RA, IL-3, IL-9, TSLP, VEGFA, VEGFC, VEGFD, VEGFR1/FLT1, PIGF, 
TIE2, FGF, ICAM1, VCAM1, SAA and CRP and read using an MSD MESO 
S600 instrument. Concentrations were calculated by comparison with 
an internal standard calibration curve fitted to a four-parameter logis-
tic model. Values below (19%) or above (0%) the reference range were 
imputed at the lower/upper limit of detection, respectively. Association 
of each cytokine level with SARS-CoV-2 neutralizing antibody titre, 
neutralization status (1/0) and age was undertaken using Kendall’s tau 
and Wilcoxon tests with FDR <5% considered significant.
B cell receptor repertoire library preparation
PBMCs were lysed and RNA extracted using Qiagen AllPrep DNA/RNA 
mini kits and Allprep DNA/RNA Micro kits according to the manufac-
turer’s protocol. The RNA was quantified using a Qubit. B cell receptor 
repertoire libraries were generated for 52 COVID-19 vaccinated indi-
viduals (58 samples) as follows: 200 ng total RNA from PAXgenes (14 μl 
volume) was combined with 1 μl 10 mM dNTP and 10 μM reverse primer 
mix (2 μl) and incubated for 5 min at 70 °C. The mixture was immediately 
placed on ice for 1 min and then subsequently combined with 1 μl DTT 
(0.1 M), 1 μl SuperScriptIV (Thermo Fisher Scientific), 4 μl SSIV Buffer 
(Thermo Fisher Scientific) and 1 μl RNase inhibitor. The solution was 
incubated at 50 °C for 60 min followed by 15 min inactivation at 70 °C. 
cDNA was cleaned with AMPure XP beads and PCR-amplified with a 5′ 
V-gene multiplex primer mix and 3′ universal reverse primer using the 
KAPA protocol and the following thermal cycling conditions: 1 cycle 
(95 °C, 5 min); 5 cycles (98 °C, 20 s; 72 °C, 30 s); 5 cycles (98 °C, 15 s; 65 °C, 
30 s; 72 °C, 30 s); 19 cycles (98 °C, 15 s; 60 °C, 30 s; 72 °C, 30 s); 1 step (72 °C, 
5 min). Sequencing libraries were prepared using Illumina protocols and 
sequenced using 300-bp paired-end sequencing on a MiSeq machine.
Sequence analysis
Raw reads were filtered for base quality using a median Phred score 
of ≥ 32 (http://sourceforge.net/projects/quasr/). Forward and reverse 
reads were merged where a minimum 20-bp identical overlapping 
region was present. Sequences were retained where more than 80% base 
sequence similarity was present between all sequences with the same 
barcode. The constant-region allele with highest sequence similarity 
was identified by 10-mer matching to the reference constant-region 
genes from the IMGT database. Sequences without complete reading 
frames and non-immunoglobulin sequences were removed and only 
reads with significant similarity to reference IGHV and J genes from 
the IMGT database using BLAST were retained. Immunoglobulin gene 
use and sequence annotation were performed in IMGT V-QUEST, and 
repertoire differences were analysed by custom scripts in Python.
Public BCR analysis
Convergent clones were annotated with the same IGHV and IGHJ seg-
ments, had the same CDR-H3 region length and were clustered based on 
85% CDR-H3 sequence amino acid homology. A cluster was considered 
convergent with the CoV-AbDab database if it contained sequences 
from post-vaccinated individuals and from the database.
Flow cytometry
The following antibodies or staining reagents were purchased from 
BioLegend: CD19 (SJ25C, 363028), CD3 (OKT3, 317328), CD11C (3.9, 
301608), CD25 (M-A251, 356126), CD14 (M5E2,301836), and IgM 
(IgG1-k, 314524). CCR7 (150503, 561143) and IgG (G18-145, 561297) 
were obtained from BD Bioscience, CD45RA (T6D11, 130-113-359) from 
Miltyeni Biotech, and CD8A (SK1, 48-0087-42) from eBiosciences. 
The LIVE/DEAD Fixable Aqua Dead Cell Stain Kit was obtained from 
Invitrogen. Biotinylated spike protein expressed and purified as pre-
viously described26 was conjugated to streptavidin R-phycoerythrin 
(PJRS25-1) or streptavidin APC obtained from Agilent Technologies. 
PBMCs were isolated from study participants and stored in liquid 
nitrogen. Aliquots containing 107 cells were thawed and stained in 
PBS containing 2 mM EDTA at 4 °C with the above antibody panel 
and then transferred to 0.04% BSA in PBS. Events were acquired on 
a FACSAria Fusion (BD Biosciences). Analyses were carried out in 
FlowJo version 10.7.1.
IFNγ and IL-2 FluoroSpot T cell assays
PBMCs were isolated from the heparinized blood samples using 
Histopaque-1077 (Sigma-Aldrich) and SepMate-50 tubes (StemCell 
Technologies). Frozen PBMCs were rapidly thawed and diluted into 10 
ml TexMACS medium (Miltenyi Biotech), centrifuged and resuspended 
in 10 ml fresh medium with 10 U/ml DNase (Benzonase, Merck-Millipore 
via Sigma-Aldrich). PBMCs were then incubated at 37 °C for 1 h, followed 
by centrifugation and resuspension in fresh medium supplemented 
with 5% human AB serum (Sigma Aldrich) before being counted. PBMCs 
were stained with 2 μl LIVE/DEAD Fixable Far Red Dead Cell Stain Kit 
(Thermo Fisher Scientific) and live PBMCs were enumerated on the BD 
Accuri C6 flow cytometer.
Overlapping spike SARS-CoV-2 peptide stimulation
A peptide pool was generated using the following: 1. PepTivator 
SARS-CoV-2 Prot_S containing the sequence domains (amino acids) 
304–338, 421–475, 492–519, 683–707, 741–770, 785–802, and 885–
1,273 and the N-terminal S1 domain of the surface glycoprotein (S) 
of SARS-CoV-2 (GenBank MN908947.3, Protein QHD43416.1). 2. The 
PepTivator SARS-CoV-2 Prot_S1 containing amino acids 1–692. The 
peptides used are 15 amino acids with 11-amino acid overlaps.
We incubated 1.0 to 2.5 × 105 PBMCs from vaccinated individuals in 
pre-coated FluoroSpotFLEX plates (anti-IFNγ and anti-IL-2 capture antibod-
ies, Mabtech) in duplicate with the spike peptide pool mix as described 
above (specific for Wuhan-1, QHD43416.1 spike SARS-CoV-2 protein; 
Miltenyi Biotech) or a mixture of peptides specific for cytomegalovirus, 
Epstein–Barr virus and influenza virus (CEF+, Miltenyi Biotech) (final 
peptide concentration as recommended by the manufacturer: 1 μg/
ml/peptide) in addition to an unstimulated (medium only) and positive 
control mix (containing anti-CD3 (Mabtech AB) and Staphylococcus 
Enterotoxin B (SEB, Sigma Aldrich)) at 37 °C in a humidified CO2 atmos-
phere for 42 h. The cells and medium were then decanted from the plate 
and the assay developed according to the manufacturer’s instructions. 
Developed plates were read using an AID iSpot reader (Oxford Biosys-
tems) and counted using AID EliSpot v7 software (Autoimmun Diag-
nostika). Peptide-specific frequencies were calculated by subtracting 
for background cytokine-specific spots (unstimulated control) and 
expressed as SFU per 106 PBMCs. With the same peptide pool, we also 
stimulated PBMC that had been collected and biobanked between 2014 
and 2016, representing a healthy population that had not been exposed 
to SARS-CoV-2, and PBMCs from donors who had been infected with 
SARS-CoV-2 (confirmed by RT–PCR) for comparison of T cell responses 
following natural infection.
CD4 and CD8 depletion from PBMCs for subsequent FluoroSpot 
analysis
Peripheral blood mononuclear cells were depleted of either CD4+ or 
CD8+ T cells by magnetic-activated cell sorting (MACS) using anti-CD4 
or anti-CD8 direct beads (Miltenyi Biotec), according to the manufac-
turer’s instructions, and separated using an AutoMACS Pro (Miltenyi 
Biotec). The efficiency of depletion was determined by staining cells 
with a mix of CD3-FITC, CD4-PE, and CD8-PerCPCy5.5 antibodies (all 
BioLegend) and analysing by flow cytometry.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
Sequence data have been deposited at the European Genome-Phenome 
Archive (https://ega-archive.org/) which is hosted by the EBI and the 
CRG under accession number EGAS00001005380. Data are available 
without restriction.
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Extended Data Fig. 1 | Study flow diagram for samples and analyses. n values are shown for each analysis.
Extended Data Fig. 2 | SARS-CoV-2 neutralization by serum from 
individuals vaccinated with Pfizer BNT162b2 vaccine. a, Linear correlation 
of live virus neutralization with SARS-CoV-2 spike PV neutralization for 13 sera 
from individuals vaccinated with BNT162b2. Linear regression line plotted 
bounded by 95% CI. b, SARS-CoV-2 PV neutralization by sera from individuals 
vaccinated with first dose of BNT162b2 (n = 140) plotted against time since first 
dose. c, Correlation of SARS-CoV-2 neutralization by sera from individuals 
vaccinated with BNT162b2 with age. Serum neutralization of spike (D614G) 
pseudotyped lentiviral particles (ID50) after dose 1 (top, n = 138) or dose 2 
(bottom, n = 64) by age. Linear regression line plotted bounded by 95% CI. 
Bonferroni adjustment was made for multiple comparisons in linear 
regression. d, ID50 against wild-type (D614G) PV following the second dose of 
vaccine stratified by age and interval between vaccine doses (3 weeks (n = 21) 
and 12 weeks (n = 43)). GMT ± s.d., Mann–Whitney test. e, Spike mutations in 
VOCs, along with number of sequences in GISAID database.
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Extended Data Fig. 3 | Binding IgG and IgA spike antibody responses 
following BNT162b2 vaccination. a, Correlations between serum binding IgG 
subclass 1–4 antibody responses following vaccination with first dose of 
BNT162b2 and age in years (n = 133). b, Correlations between serum binding IgG 
subclass 1–4 antibody responses following vaccination with first dose of 
BNT162b2 and serum neutralization using a PV system (n = 133). c, IgA 
responses to spike, nucleocapsid and RBD after first dose (light green, n = 133) 
and second dose (dark green, n = 21) compared to individuals with prior 
infection (red, n = 18) and negative controls (grey, n = 18) at serum dilution of 1 
in 100. d, Correlations between serum binding IgA spike antibody responses 
following vaccination with first dose of BNT162b2 and serum neutralization 
using a PV system (n = 133). Bonferroni adjustment was made for multiple 
comparisons. Spike proteins tested are Wuhan-1 with D614G (WT). Linear 
regression lines plotted bounded by 95% CI.
Extended Data Fig. 4 | Peripheral blood lymphocyte subsets following first 
dose of BNT162b2. PBMCs were sorted by FACS (n = 16 above 80 years of age, 
n = 16 below 80 years of age). a, Gating strategy for flow cytometry analysis of 
human immune cells after vaccination. b, Data for indicated sorted cell subsets 
stratified by neutralizing response after first dose (n = 8 in each category). NK 
cells, natural killer cells; Treg cells, regulatory T cells. Error bars, s.d.
Article
Extended Data Fig. 5 | B cell repertoire following vaccination with first dose 
of BNT162b2. a, Isotype usage according to unique VDJ sequence in 
<80-year-old (n = 22) and ≥80-year-old groups (n = 28). Differences between 
groups were calculated using Mann–Whitney U-test. b, V gene usage as a 
proportion, by neutralization of spike PV. Neutralization cut-off for 50% 
neutralization was set at 20. Differences between groups were calculated using 
Mann–Whitney U-test. c, Diversity indices comparing the two age groups. The 
inverse is depicted for Simpson’s index and the Shannon–Weiner index is 
normalized. Differences between groups were calculated using a t-test. For 
boxplots: centre line, median; box, 25th–75th percentile; whiskers, 1.5× IQR.
Extended Data Fig. 6 | See next page for caption.
Article
Extended Data Fig. 6 | T cell responses following vaccination with 
BNT162b2. Correlation between T cell responses against SARS-CoV-2 spike 
peptide pool and serum neutralization of spike (D614G) pseudotyped lentiviral 
particles (ID50). a, b, Correlation of IFNγ (a, n = 79) and IL-2 (b, n = 69) 
FluoroSpot and ID50 after first dose. Linear regression lines with 95% CI are 
plotted. Bonferroni adjustment was made for multiple comparisons.  
c, FluoroSpot IFNγ PBMC responses to peptide pool of CEF peptide pool. 
Responses from unexposed PBMCs (stored from 2014–2016, n = 20), <80 years 
group (n = 46) and ≥80 years group (n = 35) three weeks after the first dose  
of vaccine. d, e, FluoroSpot analysis for IFNγ (d) and IL-2 T cell responses (e) 
specific to SARS-CoV-2 spike protein peptide pool following stimulation of 
PBMCs from infected donors (n = 46), unexposed donors (n = 20) and 
vaccinated individuals three weeks or more after the first dose (IFNγ, n = 77;  
IL-2, n = 64) and three weeks after the second dose (IFNγ and IL-2, n = 39).  
f–i, Human cytomegalovirus serostatus, T cell responses and serum 
neutralization of spike (D614G) pseudotyped lentiviral particles (ID50) after 
the first dose of vaccine. f, HCMV serostatus for <80- and ≥80-year age groups 
(n = 72). g, h, IFNγ (g, n = 72) and IL-2 (h, n = 64) FluoroSpot responses after the 
first dose. i, ID50 after the first dose by CMV serostatus. Error bars, s.d.
Extended Data Fig. 7 | Autoantibodies and inflammatory markers in 
participants who received at least one dose of the BNT162b2 vaccine and 
relationship to SARS-CoV-2 spike-specific IgG and SARS-CoV-2 PV 
neutralization. n = 101. a, Heatmap of log2-transformed fluorescence intensity 
of 19 autoantibodies; red, positive; blue, negative. b, Age (mean ± s.d.) in years 
by anti-MPO antibody-positive (red) or -negative (blue) status. c, IgG subclass 
responses to spike after first dose of BNT162b2 vaccine in individuals with or 
without anti-MPO antibodies (n = 100). d, GMT ± s.d of sera from individuals 
after their first dose of vaccine against wild-type and B.1.1.7 spike mutant 
SARS-CoV-2 PVs by anti-MPO antibody status. e, Nonparametric rank 
correlation (Kendall’s tau-b) of wild-type (WT) PV neutralization, variant 
(B.1.17) PV neutralization and age (<80 or ≥80 years) against each of 53 
cytokines or chemokines. Heatmaps illustrate Tau-b statistic (left) and 
significance (right, –log10FDR).
Article




















bNeutralization data unavailable for two individuals. 
cNeutralization data unavailable for one individual. 
dMann–Whitney test. 
eNeutralization data available for 27 of 80 individuals. 
fNeutralization data available for 37 of 60 individuals. 
gTest of proportions.





























*Mutually adjusted for other variables in the table. OR, odds ratio.
Article
Extended Data Table 3 | Neutralization in participants after the first dose of BNT162b2 vaccine against wild-type and B.1.1.7, 











































*Mutually adjusted for other variables in the table.
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Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection Graphpad Prism v9 was used to produce figures. 
Stata v13 was used for statistical analyses. 
FlowJo version 10.7.1 for flow cytometry analyses. 
IMGT-V QUEST was used for immunoglobulin gene use and sequence annotation 
B cell receptor repertoire analyses was performed in Python.
Data analysis Logistic regression was used to model the association between age group and neutralisation by vaccine-elicited antibodies after the first 
dose of the BNT162b2 vaccine. The effect of sex and time interval from vaccination to sampling as confounders were adjusted for. Linear 
regression was also used to explore the association between age as a continuous variable and log transformed ID50, binding antibody 
levels, antibody subclass levels and T cell response after dose 1 and dose 2 of the BNT162b2 vaccine. 
 
The difference in continuous and categorical data were tested using Wilcoxon rank sum or Mann-Whitney test and Chi square test 
respectively.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
Sequence data have been deposited at the European Genome -phenome Archive (EGA) which is hosted by the EBI and the CRG under accession number 
EGAS00001005380.
Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size We assumed a risk ratio of non-neutralisation in the ≥80 years group compared with <80 years group of 5. Using an alpha of 0.05 and power 
of 90% required a sample size of 50 with a 1:1 ratio in each group. We however recruited 140 participants in order to reduce the risk of Type I 
error as multiple analyses were undertaken.
Data exclusions Consecutively presenting participants were recruited with no exclusion.
Replication Experiments were done in technical duplicates and a repeat was done.
Randomization Not applicable as this was not an intervention study.
Blinding Not applicable as this was not an intervention study.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems













Antibodies used anti-CD4+ or anti-CD8+ direct beads (Miltenyi Biotec) 
CD3-FITC, CD4-PE, and CD8- PerCPCy5.5 antibody (BioLegend) 
CD19 (SJ25C, 363028), CD3 (OKT3, 317328), CD11c (3.9, 301608), CD25 (M-A251, 356126), CD14 (M5E2,301836), and IgM (IgG1-
k, 314524) (all Biolegend). 
CCR7 (150503, 561143) and IgG (G18-145, 561297) (BD Biosciences) 
CD45RA (T6D11, 130-113-359) ( Miltyeni Biotech) 
CD8a (SK1, 48-0087-42) (eBiosciences) 
Validation Validation by manufacturer as detailed on their website.
3






Policy information about cell lines
Cell line source(s) HEK 293T and HeLa cells were used.
Authentication None of the cell lines used were authenticated.
Mycoplasma contamination All cell lines used were tested (by PCR) and were mycoplasma free.
Commonly misidentified lines
(See ICLAC register)
 No commonly misidentified lines were used in this study.
Human research participants
Policy information about studies involving human research participants
Population characteristics Community participants or health care workers receiving the first dose of the BNT162b2 vaccine between the 14th of December 
2020 to the 10th of February 2021 were consecutively recruited. 140 participants were recruited.
Recruitment Participants attending Addenbrooke's Hospital for their COVID-19 vaccination were recruited through the NIHR BioResource 
Centre Cambridge.
Ethics oversight The study was approved by the East of England – Cambridge Central Research Ethics Committee.




The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation PBMCs were isolated from whole blood samples using Lymphoprep and stored in liquid nitrogen. Cells were thawed and stained 
in PBS containing 2nM EDTA at 4 °C 
Instrument Instrument: FACSAria Fusion (BD Biosciences).
Software FlowJo version 10.7.1
Cell population abundance 2 x 10^5 to 2 x 10^6
Gating strategy Total lymphocytes were gated, then live dead. From live dead, CD3- and CD3+ cells were separated. CD3+ cells were separated 
into CD8- and CD8+ cells. CD8+ memory cells were determined using CCR7 and CD45RA from the CD8+ gate. From the CD8- 
gate, CD4 memory cells were determined using CCR7 and CD45RA. From the CD4 memory gate, Tregs were separated from CD4 
memory cells with CD25. The CD3- gate was used to separate CD14- and CD14+ cells. CD14- cells were separated in CD19+CD56- 
and CD19-CD56+ gates. From the CD19+ gate, B memory cells were determined using IgG and IgM. IgG+IgM- cells were gated 
and from these cells, B memory cells doubly positive for Spike were gated.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
